Journal of Cytology · Published 2026-04-01 · DOI 10.4103/joc.joc_53_26
Cervical cancer screening has evolved immensely with advances in molecular diagnostics and improved understanding of human papillomavirus (HPV)-mediated carcinogenesis. While conventional cervical cytology has historically played a pivotal role in reductions in cervical cancer incidence and mortality, its limitations have led to the development of liquid-based cytology (LBC) and HPV-based testing. LBC offers improved sample adequacy, better preservation of cellular morphology, and permits the use of residual material for ancillary testing. HPV DNA testing, particularly as a primary screening modality, provides high sensitivity for detecting high-grade cervical intraepithelial neoplasia. In addition, emerging biomarkers such as p16INK4a and Ki-67 dual staining enhance risk stratification and triage of HPV-positive women. Despite the growing adoption of primary HPV screening, cytology remains indispensable for morphologic assessment, detection of HPV-independent lesions, and clinical correlation. An integrated approach combining HPV testing, cytology, and biomarkers represents the most effective strategy for cervical cancer screening. Such a balanced model is essential for optimizing diagnostic accuracy, guiding management, and supporting global efforts toward cervical cancer elimination.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →